EGFR and colorectal carcinoma: Additional studies that include a larger set of plasma samples are needed to validate the specificity and the sensitivity of hypermethylated B4GALT1 as circulating biomarkers and to explore the value of the plasma detection of B4GALT1 in anti-EGFR therapy treated CRC in order to predict acquired resistance.